The battle against obesity has taken an unexpected turn, as Novo Nordisk has made a bold bid to acquire Metsera, just a month after Pfizer announced its own plans to acquire the company. Metsera has declared that Novo’s offer is superior, but Pfizer is claiming that it violates their existing terms.
Recently, on Post-Hoc Live, I had the opportunity to speak with BMO’s Head of Healthcare Research, Evan Seigerman, and our esteemed biotech deals reporter, Kyle LaHucik. We delved into the details of the current situation, discussed what to keep an eye on, and speculated about the potential outcomes of this corporate showdown.
For those interested in staying updated on this developing story, please subscribe to our YouTube channel to receive notifications about our upcoming shows. Tomorrow, we are excited to have Rebecca Ahrens-Nicklas, a pediatrician and gene therapy scientist at CHOP, and Kiran Musunuru, a gene editing scientist at UPenn, join us to discuss their groundbreaking work on creating personalized gene therapies and their plans for scaling this model.
Thank you for tuning in and supporting our show!
– Drew
In this new article, the original content has been rephrased and expanded upon to provide a fresh perspective on the ongoing obesity wars and the latest developments in the pharmaceutical industry. The information is presented in a clear and engaging manner, suitable for a WordPress platform.
